-
1 Comment
Regent Pacific Group Limited is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 573.0% more expensive than other stocks from the Financial Services sector with a price to sales ratio of 99.7.
Regent Pacific Group Limited's total revenue sank by 83.9% to $85K since the same quarter in the previous year.
Its net income has increased by 36.5% to $-27M since the same quarter in the previous year.
Finally, its free cash flow fell by 71.5% to $-4M since the same quarter in the previous year.
Based on the above factors, Regent Pacific Group Limited gets an overall score of 1/5.
| ISIN | KYG3042R1074 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 109M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.77 |
| Dividend Yield | None |
Regent Pacific Group Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in Europe, the United States, and the Asia Pacific. The company operates through Biopharma and Corporate Investment segments. It is involved in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management services. The company was formerly known as Endurance RP Limited and changed its name to Regent Pacific Group Limited in July 2023. Regent Pacific Group Limited was founded in 1991 and is headquartered in Central, Hong Kong.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0575.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
